Outcomes of salvage autologous stem cell transplantation for multiple myeloma with cytopenias and exposure to novel agents.

about

Outcomes of salvage autologous stem cell transplantation for multiple myeloma with cytopenias and exposure to novel agents.

Item

http://www.wikidata.org/entity/Q53146498

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Outcomes of salvage autologous ...... and exposure to novel agents.

@en

Outcomes of salvage autologous ...... and exposure to novel agents.

@nl

type

Item

label

Outcomes of salvage autologous ...... and exposure to novel agents.

@en

Outcomes of salvage autologous ...... and exposure to novel agents.

@nl

prefLabel

Outcomes of salvage autologous ...... and exposure to novel agents.

@en

Outcomes of salvage autologous ...... and exposure to novel agents.

@nl

P1476

Outcomes of salvage autologous ...... and exposure to novel agents.

@en

P2093

A Chari

http://www.w3.org/2001/XMLSchema#string

D Tremblay

http://www.w3.org/2001/XMLSchema#string

E Moshier

http://www.w3.org/2001/XMLSchema#string

G Lancman

http://www.w3.org/2001/XMLSchema#string

N Bar

http://www.w3.org/2001/XMLSchema#string

S Jagannath

http://www.w3.org/2001/XMLSchema#string

P2860

Salvage second hematopoietic cell transplantation in myeloma

Durable remission with salvage second autotransplants in patients with multiple myeloma.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma.

Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation.

Second auto-SCT for treatment of relapsed multiple myeloma.

Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT.

Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry.

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.

P2888

bmt.2017.160

P304

1468-1470

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2017.160

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28737774

http://www.w3.org/2001/XMLSchema#string